Irisys SafeCount Live Occupancy Monitoring Solution Automates Occupancy Compliance and Enables Social Distancing for Buildings and Rooms With One or Multiple Entrances
28.7.2020 13:00:00 EEST | Business Wire | Press release
The COVID-19 pandemic has created an urgent need to accurately and efficiently manage occupancy regulations and enable social distancing in corporate workspaces, higher education buildings, retail stores, and manufacturing facilities. The Irisys SafeCount™ Live Occupancy Monitoring Solution helps businesses comply with social distancing and occupancy guidelines by anonymously counting people as they enter and exit buildings and rooms.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200728005318/en/
Suitable for buildings of all sizes, even those with multiple entrances and exits, SafeCount delivers live occupancy data with visual warnings and alerts when limits are approached or exceeded. (Photo: Business Wire)
Suitable for buildings of all sizes, even those with multiple entrances and exits, SafeCount delivers live occupancy data with visual warnings and alerts when limits are approached or exceeded.
Built on the advanced Irisys Vector 4D people counting sensor, SafeCount features:
- Easy, fast installation — Simple setup and configuration in less than 30 minutes.
- Highly accurate — Better than 99 percent sensor accuracy that is unaffected by environmental conditions or large crowds.
- Privacy protection — no personally identifiable information is captured by the system.
- Staff detection — advanced functionality can exclude staff from occupancy count.
- Standalone system, yet scalable — SafeCount works separately from existing IT networks and you can add the optional SafeCount Plus cloud platform for remote management and reporting.
“The Irisys SafeCount dashboard puts real-time occupancy data in the hands of attendants and managers while the historical reports provide an audit trail for social distancing compliance,” said Mike Slevin, director of sales at Irisys “Perhaps more importantly, SafeCount gives customers, employees, and visitors peace of mind that your company is protecting their health and safety.”
The SafeCount Plus cloud platform supports an unlimited number of buildings in different locations and time zones. Its advanced reporting enables managers to easily review, compare and analyze occupancy data to identify locations that are not complying with occupancy restrictions, allowing them to take action.
For more information on Irisys SafeCount Live Occupancy Monitoring, visit: https://www.irisys.net/products/safecount-occupancy-monitoring-solution.
About Irisys
Infrared Integrated Systems Ltd, generally called Irisys, is the largest global provider of people counting and real-time queue management solutions. The company’s technology is use by major organizations globally in sectors varying from retail, banks, transport to leisure facilities and public buildings. The systems give operators an unprecedented insight into their business, giving them the information they need to improve customer service, operational efficiency, and profitability. Companies often find opportunities for rapid improvements in their business, and a quick return on investment.
In 2012, Irisys became part of the Fluke Corporation, a worldwide leader in calibration and handheld test instruments. Fluke is world famous for the durability of its test tools and offers a range of tough electrical test tools, infrared thermometers, thermal imagers, and other devices designed for extreme field use.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005318/en/
Contact information
Rebecca Rader
(206) 372-1159
rebecca@paynespencer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 23:22:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
